Contact dermatitis

Scheinman, Pamela L.; Vocanson, Marc; Thyssen, Jacob P.; Johansen, Jeanne Duus; Nixon, Rosemary; Dear, Kate; Botto, Nina; Morot, Johanna; Goldminz, Ari M.

doi:10.1038/s41572-021-00271-4

Cited by 81 publications

(67 citation statements)

References 384 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In case of mild disease, personal protective measures such as barrier creams, gloves and protective clothing, skin barrier repair cream, alcohol disinfection and addition of moisturizers (use of humectants and emollients) help to improve skin barrier. The mainstay of treatment is application of topical corticosteroids, often supplemented by moisturizing creams [ 64 ]. Topical calcineurin inhibitors (pimecrolimus, tacrolimus) and topical phosphodiesterase 4 inhibitor (crisaborole) are off-label use for CD but are known to be effective.…”

Section: Main Textmentioning

confidence: 99%

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

et al. 2021

View full text Add to dashboard Cite

Allergic and immunologic skin diseases negatively impact the quality of life (QoL) of affected patients with detrimental consequences. Nonetheless, in everyday clinical practice the evaluation of QoL is often overlooked. Considering the increasing prevalence of atopic dermatitis, allergic contact dermatitis, hereditary angioedema, cutaneous mastocytosis, and urticaria, it is essential to determine the effects of allergic and immunologic skin diseases on QoL. A joint meeting (GET TOGETHER 2021) of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to summarize the features of the main QoL tools used in these diseases and to describe the extent of QoL impairment as well as the impact of treatments on QoL, particularly biologic therapies. The assessment of QoL in patients with allergic and immunologic skin diseases relies on generic, organ-specific and disease-specific questionnaires. While generic and organ-specific questionnaires allow comparison between different diseases, disease-specific questionnaires are designed and validated for specific cohorts: the QoL Index for Atopic Dermatitis (QoLIAD) and the Childhood Atopic Dermatitis Impact Scale (CADIS) in atopic dermatitis, the ACD-11 in allergic contact dermatitis, the Angioedema QoL Questionnaire (AE-QoL) and the Hereditary Angioedema QoL questionnaire (HAE-QoL) in hereditary angioedema, the Mastocytosis QoL Questionnaires (MCQoL e MQLQ) in cutaneous mastocytosis, and the Chronic Urticaria QoL questionnaire (CU-Q2oL) in urticaria. Among the many factors that variably contribute to QoL impairment, pruritus can represent the leading cause of patient discomfort. Biologic therapies significantly ameliorate QoL in atopic dermatitis, hereditary angioedema, mastocytosis and chronic urticaria. In general, adequate management strategies are essential for improving QoL in patients with allergic and immunologic skin diseases.

show abstract

Section: Main Textmentioning

confidence: 99%

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Cytotoxic CD8+ T cells kill haptenized keratinocytes and induce via mobilization of further inflammatory cells the formation of eczematous skin lesions. 7 In contrast, irritant contact dermatitis occurs via a direct toxic effect on epidermal corneocytes and keratinocytes by an irritant (e.g., chemical) with subsequent barrier disruption and inflammation without involvement of adaptive immune mechanisms. Irritants may trigger cell necrosis and the release of stress signals (e.g., reactive oxygen species, ATP) and damage‐associated molecular patterns (e.g., heat‐shock proteins) which are sensed by receptors of innate immune cells.…”

Section: Introductionmentioning

confidence: 99%

“…Irritants may trigger cell necrosis and the release of stress signals (e.g., reactive oxygen species, ATP) and damage‐associated molecular patterns (e.g., heat‐shock proteins) which are sensed by receptors of innate immune cells. 7 The pathogenesis of both, allergic and irritant contact dermatitis is held to be driven, at least in part, by the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, an innate immune sensor and multimeric protein complex that initiates an inflammatory form of cell death and triggers the release of the proinflammatory cytokines IL‐1β and IL‐18. Contact allergens such as nickel, trinitro‐chlorobenzene, chromium and latex as well as the skin irritant sodium dodecyl sulfate (SDS) induce NLRP3 inflammasome‐mediated IL‐1β secretion in keratinocytes and macrophages.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis

Bonnekoh

Vera

Abad-Perez

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

Background:The pathogenesis of contact dermatitis, a common inflammatory skin disease with limited treatment options, is held to be driven by inflammasome activation induced by allergens and irritants. We here aim to identify inflammasometargeting treatment strategies for irritant contact dermatitis. Methods:A high content screen with 41,184 small molecules was performed using fluorescent Apoptosis associated speck-like protein containing a CARD (ASC) speck formation as a readout for inflammasome activation. Hit compounds were validated for inhibition of interleukin (IL)-1β secretion. Of these, the approved thiuramdisulfide derivative disulfiram was selected and tested in a patch test model of irritant contact dermatitis in 25 healthy volunteers. Topical application of disulfiram, mometasone or vehicle was followed by application of sodiumdodecylsulfate (SDS) for 24 h each. Eczema induction was quantified by mexameter and laser speckle imaging. Corneocyte sampling of lesional skin was performed to assess inflammasome-mediated cytokines IL-1β and IL-18.Results: Disulfiram induced a dose-dependent inhibition of ASC speck formation and IL-1β release in cellular assays in vitro. In vivo, treatment with disulfiram, but not with vehicle and less mometasone, inhibited SDS-induced eczema. This was demonstrated by significantly lower erythema and total perfusion values assessed by mexameter and laser speckle imaging for disulfiram compared to vehicle (p < 0.001) and/or mometasone (p < 0.001). Also, corneocyte IL-18 levels were significantly reduced after application of disulfiram compared to vehicle (p < 0.001). Conclusion:We show that disulfiram is a dose-dependent inhibitor of inflammasome pathway activation in vitro and inhibitor of SDS-induced eczema in vivo.Topical application of disulfiram represents a potential treatment option for irritant contact dermatitis.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

“…The diagnosis of ICD is a diagnosis of exclusion; diagnosis of CD relies on clinical presentation, thorough exposure assessment and a patch test (for ACD and PACD), which is the gold standard for the identification of contact allergens, or a skin-prick or prick-prick test (for PCD) [7].…”

Section: Introductionmentioning

confidence: 99%

An Overview on Contact Dermatitis: Simple Review

Alzahrani

Murad

Alatawi

et al. 2021

JPRI

View full text Add to dashboard Cite

Contact dermatitis (CD) is usually the result of cumulative exposure to sensitive irritants and accounts for 80% of all contact dermatitis cases. ICD can coexist with atopic dermatitis (AD) and allergic contact dermatitis (ACD). Patients with Alzheimer's disease and ACD may also have a lower infection threshold for ICD. Therefore, it must stand out from EA and CAD lesions. People with ICD have experienced uncontrolled tingling and burning sensations. Itching is typically manifested in patients with AD and ACD. Compared with AD and ACD, ICD lesions are usually well described. The prognosis of ICD is based on the exclusion method. Monitor patients to rule out type 1 and type 4 hypersensitivity reactions. A negative result indicates the prognosis of ICD. Management includes identifying and avoiding irritants through the normal use of emollients. Although ICD is older, it is not uncommon in some majors, and genetics and environment play a vital role in its development.

show abstract

Contact dermatitis

Cited by 81 publications

References 384 publications

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis

An Overview on Contact Dermatitis: Simple Review

Contact Info

Product

Resources

About